Pfizer reject enters Phase III for brain cancer
This article was originally published in Scrip
Executive Summary
Celldex Therapeutics has begun Phase III testing of rindopepimut in glioblastoma. Celldex regained the rights to rindopepimut, an immunotherapeutic vaccine that targets epidermal growth factor receptor variant III (EGFRvIII), last year after Pfizer informed Celldex that the rindopepimut programme was no longer a strategic priority for Pfizer.